Full-Time

Actuary III

Updated on 9/10/2026

Aflac

Aflac

10,001+ employees

Supplemental health and life insurance provider

Compensation Overview

$100k - $130k/yr

+ Annual bonuses + Company stock purchase opportunity + Incentive pay

Columbus, GA, USA + 1 more

More locations: Atlanta, GA, USA

Hybrid

At least 60% of the work week must be in the Columbus, Georgia office; the remainder may be worked from home within the continental United States.

Bachelor's

Category
Insurance (1)
Required Skills
SQL
Mainframe Computing
Data Analysis
Excel/Numbers/Sheets
Financial Modeling

Get referred to Aflac

See people who can refer or advise you

Requirements
  • Proficiency coding models in Excel, Mainframe, SQL, MG-Alfa, or similar actuarial software.
  • Advanced actuarial technical knowledge, including data analysis, actuarial and financial assumptions, and actuarial and financial modeling.
  • Advanced project management ability, including leading projects with cross-functional accountabilities.
  • Advanced communication ability to explain business issues and potential solutions to varied audiences.
  • Intermediate business knowledge and acumen linking actuarial analysis to organizational goals and business outcomes.
  • An ability to deliver results through projects, plans, priorities, and actions aligned with business initiatives and goals.
  • An ability to develop broader business acumen, create business partnerships through consulting advice, and seek mentoring opportunities.
  • An ability to influence decision makers and stakeholders by interpreting business and technical information and building agreement around recommendations.
  • Advanced decision-making ability using timely analysis and evaluating options despite incomplete data.
  • An ability to adhere to professional standards of conduct and interact with others respectfully and objectively.
  • A bachelor's degree in actuarial science, mathematics, computer science, or a related field.
  • An Associate of the Society of Actuaries designation from the Society of Actuaries is required, with commitment to continue toward the Fellow of the Society of Actuaries designation.
  • Current candidacy in, or qualification to become a candidate in, the Aflac Actuarial Development Program.
  • Three years of professional job-related work experience, or an equivalent combination of education and experience.
  • Knowledge of actuarial standards of practice and business acumen.
  • Ability to review and analyze statistical data, including morbidity, mortality, and termination experience, as well as policy provisions, state regulations, and other documents.
  • Ability to use judgment and business acumen to plan and accomplish goals where limited experience exists.
  • Ability to communicate actuarial findings to managers and executives in a manner appropriate for business decisions.
  • Ability to represent the department in internal and external groups.
Responsibilities
  • Analyze actuarial questions using knowledge of actuarial standards of practice and business acumen.
  • Work with product development, financial, compliance, and Japanese colleagues to complete assignments on schedule.
  • Review and analyze statistical data, including morbidity, mortality, and termination experience, as well as policy provisions, state regulations, and other documents.
  • Communicate actuarial findings to managers and executives to support business decisions.
  • Represent the department in internal and external groups for the benefit of Aflac.
  • Perform other duties as required.

Aflac provides supplemental health and life insurance products to individuals and families, operating mainly in two regions: Aflac Japan and Aflac U.S. Its policies are designed to cover out-of-pocket costs from health events and income loss, including cancer, critical illness, accidents, hospital stays, and life events. These benefits are paid directly to policyholders to help manage medical expenses not fully covered by primary insurance. The products are distributed through a network of independent agents, brokers, and financial advisors, enabling a high-volume, low-premium model that supports a large, stable customer base and ongoing revenue. Japan is its largest market, and the company uses this broad distribution and scale to differentiate itself from competitors. The goal is to provide straightforward financial protection against unexpected health-related costs while expanding its presence in the U.S. and Japanese markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

Columbus, Georgia

Founded

1955

Get referred to Aflac

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 Japan pretax margin rose to 35%, up 320 basis points.
  • Aflac returned $1.3 billion in Q2 2026 through buybacks and dividends.
  • September 2026 careers page showed 22 open roles, not a downsizing posture.

What critics are saying

  • August 12, 2026 data-breach litigation survived dismissal, raising remediation and settlement costs.
  • Japan sales fell 5.6% in Q2 2026 after Miraito comparisons, slowing growth.
  • A prolonged Japan premium slump and claims pressure can cap valuation expansion.

What makes Aflac unique

  • Aflac Japan still dominates supplemental cancer coverage, anchoring deep brand recognition.
  • Independent agents and brokers create low-cost distribution across the U.S. and Japan.
  • Regular yen bond access funds Japan growth and diversifies capital sources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Holidays

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Sep 8th, 2026
Aflac shares lag insurance sector ETF despite $61.7B market cap and Japan cancer insurance leadership

Aflac shares have underperformed the broader insurance sector, rising just 1.7% over the past three months compared to a 12.4% gain for the iShares U.S. Insurance ETF. The Columbus, Georgia-based supplemental insurance provider, valued at $61.7 billion, trades 10% below its July 52-week high of $130.22. The company's recent second-quarter results disappointed investors, with adjusted earnings of $1.75 missing expectations and revenue falling 1% year-over-year to $4.1 billion. Higher benefits and claims pressured profitability at Aflac U.S., whilst operations in Japan showed signs of slowing. Analysts have grown cautious about Aflac's growth prospects, questioning whether its core businesses can deliver sufficient expansion beyond share buybacks. The stock has dipped below its 50-day moving average, suggesting weakened near-term momentum despite holding above its 200-day average for most of the past year.

Yahoo Finance
Aug 15th, 2026
Aflac Q2 revenue falls 6.9% as Japan sales decline after Miraito cancer insurance launch

Aflac's second quarter results disappointed investors despite meeting Wall Street expectations, with revenue declining 6.9% year-on-year to $4.22 billion. The insurance giant attributed the sales drop largely to difficult comparisons following last year's launch of its Miraito cancer insurance product in Japan. Chief Executive Daniel Amos said new Japanese offerings like Tsumitasu and Anshin Palette generated solid growth. US sales grew modestly, supported by group voluntary products and network dental and vision offerings. During the earnings call, analysts pressed management on several key issues. Questions focused on the sustainability of asset repositioning efforts, appetite for larger acquisitions, sequential declines in Japanese medical sales, and the impact of inflation on policy lapse rates. Amos said Aflac remains open to strategic acquisitions but will maintain discipline, favouring smaller deals that fit operationally and financially.

Yahoo Finance
Aug 11th, 2026
Aflac Q2 sales fall 6.9% to $4.22B as Japan product refresh and U.S. group growth offset decline

Aflac reported second-quarter revenue of $4.22 billion, meeting Wall Street expectations but declining 6.9% year on year. Adjusted earnings per share of $1.75 also met analyst estimates. The supplemental insurance provider attributed the revenue decline to tough comparisons in Japan following last year's cancer insurance product launch and shifting consumer preferences. However, CEO Daniel Amos highlighted solid growth from new offerings including Tsumitasu and Anshin Palette. In the US, group voluntary products and network dental and vision sales showed strength, with dental and vision product sales rising 47%. The company maintained expense discipline despite inflationary pressures. Looking ahead, Aflac plans to focus on product innovation in Japan, continued US group product momentum, and enhanced capital management. Management emphasised its commitment to dividend growth and share repurchases.

Yahoo Finance
Aug 6th, 2026
Aflac misses Q2 revenue estimates as sales fall 9.2% to $4.12B

Aflac reported second-quarter revenue of $4.12 billion, missing analyst estimates of $4.23 billion and marking a 9.2% year-on-year decline. The supplemental insurance provider's adjusted earnings per share of $1.75 met expectations. The company's book value per share reached $60.35, beating estimates by 9.3% and showing 18.7% year-on-year growth. Pre-tax profit was $995 million, with a 24.2% margin. Chairman and CEO Daniel P. Amos highlighted solid earnings execution and new opportunities in Japan through products including Anshin Palette medical insurance and Miraito cancer insurance. In the US, Aflac is focusing on supplemental health products for employers. Over the past five years, Aflac's revenue has declined at a 5.1% annual rate, reflecting ongoing demand challenges.

PR Newswire
Aug 6th, 2026
Aflac reports Q2 net earnings of $825M, declares $0.61 quarterly dividend

Aflac Incorporated reported second quarter 2026 results with net earnings of $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago. Total revenues decreased 1.0% to $4.1 billion. Adjusted earnings were $883 million, down 7.7% from $957 million in the prior year quarter. Adjusted earnings per diluted share decreased 1.7% to $1.75. The company returned $1.3 billion to shareholders through $983 million in share repurchases and $309 million in dividends. Chairman and CEO Daniel Amos highlighted successful product initiatives in Japan and focus on supplemental health products in the US. The board declared a third quarter dividend of $0.61 per share, payable on 1 September 2026 to shareholders of record on 19 August 2026.